Analytical Data
-
Gene name
ZMYND19
- Application
-
Alternative Names
ZMYND19；MIZIP；Zinc finger MYND domain-containing Protein 19
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96E35
-
Expression Region
1-227aa
-
AA Sequence
MTDFKLGIVR LGRVAGKTKY TLIDEQDIPL VESYSFEARM EVDADGNGAK IFAYAFDKNR GRGSGRLLHE LLWERHRGGV APGFQVVHLN AVTVDNRLDN LQLVPWGWRP KAEETSSKQR EQSLYWLAIQ QLPTDPIEEQ FPVLNVTRYY NANGDVVEEE ENSCTYYECH YPPCTVIEKQ LREFNICGRC QVARYCGSQC QQKDWPAHKK HCRERKRPFQ HELEPER
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ZMYND19, a member of the ZMYND family of proteins, has garnered increasing attention in the field of molecular biology due to its involvement in various cellular processes, including transcription regulation, DNA damage response, and histone modification. Recent studies have indicated that ZMYND19 plays a critical role in cancer biology, particularly in the context of tumor progression and metastasis, as it is often dysregulated in several cancer types. The protein is known to interact with chromatin and has been linked to the modulation of gene expression through its role as a co-regulator of transcription factors. Given its potential as a biomarker and therapeutic target, the development of recombinant ZMYND19 protein for functional studies becomes essential to elucidate its mechanistic pathways. This research may provide insights into the molecular underpinnings of diseases associated with ZMYND19 dysregulation, contributing to the identification of novel therapeutic strategies in oncology. Thus, the characterization of ZMYND19 through recombinant protein expression not only aids in understanding its biological functions but also paves the way for future investigations aimed at exploiting ZMYND19 in clinical settings.
